Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-06-21

AUTHORS

Susumu Nakata, Tatsushi Yoshida, Mano Horinaka, Takumi Shiraishi, Miki Wakada, Toshiyuki Sakai

ABSTRACT

Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics. More... »

PAGES

6261-6271

References to SciGraph publications

  • 2003-03-18. Interferon-α sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-κB inactivation in ONCOGENE
  • 2001-08-01. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity in NATURE MEDICINE
  • 2003-01. Apo2L/TRAIL and its death and decoy receptors in CELL DEATH & DIFFERENTIATION
  • 2000-11-23. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites in ONCOGENE
  • 1997-10. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene in NATURE GENETICS
  • 2000-01. The language of covalent histone modifications in NATURE
  • 2002-09-05. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells in ONCOGENE
  • 2000-03-30. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site in ONCOGENE
  • 1999-11-11. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest in ONCOGENE
  • 2000-05. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand in NATURE MEDICINE
  • 2003-04-03. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway in ONCOGENE
  • 2001-04-01. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions in NATURE MEDICINE
  • 2003-10-30. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y in ONCOGENE
  • 1999-04-08. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells in ONCOGENE
  • 2002-04-18. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway in ONCOGENE
  • 1999-02. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo in NATURE MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/sj.onc.1207830

    DOI

    http://dx.doi.org/10.1038/sj.onc.1207830

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1049638392

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15208660


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Apoptosis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Apoptosis Regulatory Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "BH3 Interacting Domain Death Agonist Protein", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blotting, Western", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carrier Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Caspases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Activation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Histone Deacetylase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hydrolysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Membrane Glycoproteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Promoter Regions, Genetic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, TNF-Related Apoptosis-Inducing Ligand", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, Tumor Necrosis Factor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "TNF-Related Apoptosis-Inducing Ligand", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Cells, Cultured", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Necrosis Factor-alpha", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Up-Regulation", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nakata", 
            "givenName": "Susumu", 
            "id": "sg:person.015054254665.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015054254665.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yoshida", 
            "givenName": "Tatsushi", 
            "id": "sg:person.01265513077.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265513077.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Applied Biochemistry, Kyoto Prefectural University, 606-8522, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.258797.6", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
                "Department of Applied Biochemistry, Kyoto Prefectural University, 606-8522, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Horinaka", 
            "givenName": "Mano", 
            "id": "sg:person.01217377677.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217377677.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Urology, Kyoto Prefectural University of Medicine, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
                "Department of Urology, Kyoto Prefectural University of Medicine, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shiraishi", 
            "givenName": "Takumi", 
            "id": "sg:person.01356657633.67", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356657633.67"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wakada", 
            "givenName": "Miki", 
            "id": "sg:person.0664220600.60", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664220600.60"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sakai", 
            "givenName": "Toshiyuki", 
            "id": "sg:person.011042136772.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011042136772.64"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.onc.1203025", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032194524", 
              "https://doi.org/10.1038/sj.onc.1203025"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203963", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006747665", 
              "https://doi.org/10.1038/sj.onc.1203963"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1205345", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015264205", 
              "https://doi.org/10.1038/sj.onc.1205345"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1202543", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031105532", 
              "https://doi.org/10.1038/sj.onc.1202543"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203489", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045600742", 
              "https://doi.org/10.1038/sj.onc.1203489"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cdd.4401187", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000537525", 
              "https://doi.org/10.1038/sj.cdd.4401187"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206139", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023435255", 
              "https://doi.org/10.1038/sj.onc.1206139"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/86397", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004368073", 
              "https://doi.org/10.1038/86397"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/91000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047281881", 
              "https://doi.org/10.1038/91000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206290", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047996205", 
              "https://doi.org/10.1038/sj.onc.1206290"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/75045", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044338034", 
              "https://doi.org/10.1038/75045"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1207091", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020888713", 
              "https://doi.org/10.1038/sj.onc.1207091"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/47412", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025852070", 
              "https://doi.org/10.1038/47412"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/5517", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010598958", 
              "https://doi.org/10.1038/5517"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng1097-141", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040087526", 
              "https://doi.org/10.1038/ng1097-141"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1205897", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028847663", 
              "https://doi.org/10.1038/sj.onc.1205897"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-06-21", 
        "datePublishedReg": "2004-06-21", 
        "description": "Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/sj.onc.1207830", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1097543", 
            "issn": [
              "0950-9232", 
              "1476-5594"
            ], 
            "name": "Oncogene", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "37", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "23"
          }
        ], 
        "keywords": [
          "tumor necrosis factor-related apoptosis-inducing ligand", 
          "histone deacetylase inhibitors", 
          "death receptor 5", 
          "trichostatin A", 
          "human malignant tumor cells", 
          "TRAIL-induced apoptosis", 
          "malignant tumor cells", 
          "caspase-8", 
          "death receptor family members", 
          "receptor 5", 
          "Human recombinant DR5/Fc chimera protein", 
          "deacetylase inhibitors", 
          "DR5 mRNA", 
          "normal human peripheral blood mononuclear cells", 
          "human peripheral blood mononuclear cells", 
          "luciferase promoter assays", 
          "peripheral blood mononuclear cells", 
          "tumor cells", 
          "DR5/Fc chimera protein", 
          "cancer therapeutics", 
          "blood mononuclear cells", 
          "DR5 promoter activity", 
          "receptor family members", 
          "necrosis factor-related apoptosis-inducing ligand", 
          "factor-related apoptosis-inducing ligand", 
          "new cancer therapeutics", 
          "HL-60 cells", 
          "Bid cleavage", 
          "apoptosis-inducing ligand", 
          "promoter assays", 
          "promoter activity", 
          "chimera protein", 
          "pancaspase inhibitor", 
          "DR5 protein", 
          "time-dependent manner", 
          "mononuclear cells", 
          "Jurkat cells", 
          "DR5 expression", 
          "suboptimal concentrations", 
          "apoptosis", 
          "sodium butyrate", 
          "protein", 
          "cancer cells", 
          "RNase protection", 
          "inhibitors", 
          "cells", 
          "family members", 
          "mRNA", 
          "therapeutics", 
          "promising strategy", 
          "combined use", 
          "dose", 
          "Jurkat", 
          "receptors", 
          "treatment", 
          "expression", 
          "cleavage", 
          "activation", 
          "assays", 
          "APO2", 
          "butyrate", 
          "members", 
          "ligands", 
          "activity", 
          "manner", 
          "protection", 
          "concentration", 
          "ability", 
          "use", 
          "candidates", 
          "strategies", 
          "promising candidate", 
          "results"
        ], 
        "name": "Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells", 
        "pagination": "6261-6271", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1049638392"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/sj.onc.1207830"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15208660"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/sj.onc.1207830", 
          "https://app.dimensions.ai/details/publication/pub.1049638392"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T20:50", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_388.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/sj.onc.1207830"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1207830'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1207830'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1207830'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1207830'


     

    This table displays all metadata directly associated to this object as RDF triples.

    323 TRIPLES      21 PREDICATES      135 URIs      110 LITERALS      27 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/sj.onc.1207830 schema:about N01d0b12de81d46eebe91012ad80d05da
    2 N218f2eafee01471792a663562441c878
    3 N385ce654fc4e430fa2e40e5bf9eaca6d
    4 N4ca99ec4f7df406094451969806124e2
    5 N55b1a8592ff04ac394595bf301d5f454
    6 N5b15c6d8d84a46b4bd8367e30b1c2ede
    7 N64a7d0a5c8b949b58172873608a35f79
    8 N663e0bf10e594a6bbc4865de86f41dff
    9 N69953aad146f4a43ba4ac9d7f91619f8
    10 N8b90fc502d064c0dae440df2afee1538
    11 N9ff09f587c4e4a6daf408208af31cfbf
    12 Na61081a1857b45b389feef4fb77858f6
    13 Nbe2c43c573ee47a8907c4c626b4492d8
    14 Nbefb4b63332e485aa380d8aa6b2416af
    15 Nc16ea0fe8c5040c8be47b5faef76677f
    16 Ndc789d10d0e547b6856fb5b20d776c48
    17 Ndec86cafc3e64d7399a9604f07412e7b
    18 Nf42354499f3d4bbe995670bd5cba89e2
    19 Nf72f8fd474b24ed88d51219188bda0f0
    20 Nf8e8dc09e48640c6a9dac8354067fdf9
    21 anzsrc-for:11
    22 anzsrc-for:1103
    23 anzsrc-for:1112
    24 schema:author Nfde2584d90e24ca7aaf7bff336f22b34
    25 schema:citation sg:pub.10.1038/47412
    26 sg:pub.10.1038/5517
    27 sg:pub.10.1038/75045
    28 sg:pub.10.1038/86397
    29 sg:pub.10.1038/91000
    30 sg:pub.10.1038/ng1097-141
    31 sg:pub.10.1038/sj.cdd.4401187
    32 sg:pub.10.1038/sj.onc.1202543
    33 sg:pub.10.1038/sj.onc.1203025
    34 sg:pub.10.1038/sj.onc.1203489
    35 sg:pub.10.1038/sj.onc.1203963
    36 sg:pub.10.1038/sj.onc.1205345
    37 sg:pub.10.1038/sj.onc.1205897
    38 sg:pub.10.1038/sj.onc.1206139
    39 sg:pub.10.1038/sj.onc.1206290
    40 sg:pub.10.1038/sj.onc.1207091
    41 schema:datePublished 2004-06-21
    42 schema:datePublishedReg 2004-06-21
    43 schema:description Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.
    44 schema:genre article
    45 schema:isAccessibleForFree false
    46 schema:isPartOf N09333b3c8903452784afd464ebe6e70c
    47 N6d91bb4b14e940d283dbd5cbd6163fee
    48 sg:journal.1097543
    49 schema:keywords APO2
    50 Bid cleavage
    51 DR5 expression
    52 DR5 mRNA
    53 DR5 promoter activity
    54 DR5 protein
    55 DR5/Fc chimera protein
    56 HL-60 cells
    57 Human recombinant DR5/Fc chimera protein
    58 Jurkat
    59 Jurkat cells
    60 RNase protection
    61 TRAIL-induced apoptosis
    62 ability
    63 activation
    64 activity
    65 apoptosis
    66 apoptosis-inducing ligand
    67 assays
    68 blood mononuclear cells
    69 butyrate
    70 cancer cells
    71 cancer therapeutics
    72 candidates
    73 caspase-8
    74 cells
    75 chimera protein
    76 cleavage
    77 combined use
    78 concentration
    79 deacetylase inhibitors
    80 death receptor 5
    81 death receptor family members
    82 dose
    83 expression
    84 factor-related apoptosis-inducing ligand
    85 family members
    86 histone deacetylase inhibitors
    87 human malignant tumor cells
    88 human peripheral blood mononuclear cells
    89 inhibitors
    90 ligands
    91 luciferase promoter assays
    92 mRNA
    93 malignant tumor cells
    94 manner
    95 members
    96 mononuclear cells
    97 necrosis factor-related apoptosis-inducing ligand
    98 new cancer therapeutics
    99 normal human peripheral blood mononuclear cells
    100 pancaspase inhibitor
    101 peripheral blood mononuclear cells
    102 promising candidate
    103 promising strategy
    104 promoter activity
    105 promoter assays
    106 protection
    107 protein
    108 receptor 5
    109 receptor family members
    110 receptors
    111 results
    112 sodium butyrate
    113 strategies
    114 suboptimal concentrations
    115 therapeutics
    116 time-dependent manner
    117 treatment
    118 trichostatin A
    119 tumor cells
    120 tumor necrosis factor-related apoptosis-inducing ligand
    121 use
    122 schema:name Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
    123 schema:pagination 6261-6271
    124 schema:productId N02246e967dfa43c48b25c3dc75b7a2cf
    125 N9463d0a480e54bec90e229d649953191
    126 Nafc4858600b84942861845d853b33b87
    127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049638392
    128 https://doi.org/10.1038/sj.onc.1207830
    129 schema:sdDatePublished 2022-11-24T20:50
    130 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    131 schema:sdPublisher Nf6fa3d408c7f4124b112236a8861664e
    132 schema:url https://doi.org/10.1038/sj.onc.1207830
    133 sgo:license sg:explorer/license/
    134 sgo:sdDataset articles
    135 rdf:type schema:ScholarlyArticle
    136 N01d0b12de81d46eebe91012ad80d05da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Apoptosis
    138 rdf:type schema:DefinedTerm
    139 N02246e967dfa43c48b25c3dc75b7a2cf schema:name doi
    140 schema:value 10.1038/sj.onc.1207830
    141 rdf:type schema:PropertyValue
    142 N09333b3c8903452784afd464ebe6e70c schema:volumeNumber 23
    143 rdf:type schema:PublicationVolume
    144 N218f2eafee01471792a663562441c878 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Caspases
    146 rdf:type schema:DefinedTerm
    147 N385ce654fc4e430fa2e40e5bf9eaca6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Humans
    149 rdf:type schema:DefinedTerm
    150 N4ca99ec4f7df406094451969806124e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Receptors, Tumor Necrosis Factor
    152 rdf:type schema:DefinedTerm
    153 N55b1a8592ff04ac394595bf301d5f454 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Histone Deacetylase Inhibitors
    155 rdf:type schema:DefinedTerm
    156 N5b15c6d8d84a46b4bd8367e30b1c2ede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Promoter Regions, Genetic
    158 rdf:type schema:DefinedTerm
    159 N64a7d0a5c8b949b58172873608a35f79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Tumor Necrosis Factor-alpha
    161 rdf:type schema:DefinedTerm
    162 N663e0bf10e594a6bbc4865de86f41dff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Enzyme Activation
    164 rdf:type schema:DefinedTerm
    165 N69953aad146f4a43ba4ac9d7f91619f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Membrane Glycoproteins
    167 rdf:type schema:DefinedTerm
    168 N6d91bb4b14e940d283dbd5cbd6163fee schema:issueNumber 37
    169 rdf:type schema:PublicationIssue
    170 N8b90fc502d064c0dae440df2afee1538 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Blotting, Western
    172 rdf:type schema:DefinedTerm
    173 N9463d0a480e54bec90e229d649953191 schema:name dimensions_id
    174 schema:value pub.1049638392
    175 rdf:type schema:PropertyValue
    176 N9f7f9dd66ccb4b8cb7829f72a6807647 rdf:first sg:person.01265513077.75
    177 rdf:rest Nba632e1237e24d6fbdc788680627d072
    178 N9ff09f587c4e4a6daf408208af31cfbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Cell Line, Tumor
    180 rdf:type schema:DefinedTerm
    181 Na61081a1857b45b389feef4fb77858f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Enzyme Inhibitors
    183 rdf:type schema:DefinedTerm
    184 Na6581107bbef4874a71c7199786996b5 rdf:first sg:person.01356657633.67
    185 rdf:rest Nb408c37cc5c14ffe839a44676c21c18d
    186 Nafc4858600b84942861845d853b33b87 schema:name pubmed_id
    187 schema:value 15208660
    188 rdf:type schema:PropertyValue
    189 Nb408c37cc5c14ffe839a44676c21c18d rdf:first sg:person.0664220600.60
    190 rdf:rest Nf05a3c8ca0c34255964ebc465e427b06
    191 Nba632e1237e24d6fbdc788680627d072 rdf:first sg:person.01217377677.48
    192 rdf:rest Na6581107bbef4874a71c7199786996b5
    193 Nbe2c43c573ee47a8907c4c626b4492d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Tumor Cells, Cultured
    195 rdf:type schema:DefinedTerm
    196 Nbefb4b63332e485aa380d8aa6b2416af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    197 schema:name Apoptosis Regulatory Proteins
    198 rdf:type schema:DefinedTerm
    199 Nc16ea0fe8c5040c8be47b5faef76677f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    200 schema:name Carrier Proteins
    201 rdf:type schema:DefinedTerm
    202 Ndc789d10d0e547b6856fb5b20d776c48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Hydrolysis
    204 rdf:type schema:DefinedTerm
    205 Ndec86cafc3e64d7399a9604f07412e7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name BH3 Interacting Domain Death Agonist Protein
    207 rdf:type schema:DefinedTerm
    208 Nf05a3c8ca0c34255964ebc465e427b06 rdf:first sg:person.011042136772.64
    209 rdf:rest rdf:nil
    210 Nf42354499f3d4bbe995670bd5cba89e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    211 schema:name Up-Regulation
    212 rdf:type schema:DefinedTerm
    213 Nf6fa3d408c7f4124b112236a8861664e schema:name Springer Nature - SN SciGraph project
    214 rdf:type schema:Organization
    215 Nf72f8fd474b24ed88d51219188bda0f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    216 schema:name Receptors, TNF-Related Apoptosis-Inducing Ligand
    217 rdf:type schema:DefinedTerm
    218 Nf8e8dc09e48640c6a9dac8354067fdf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    219 schema:name TNF-Related Apoptosis-Inducing Ligand
    220 rdf:type schema:DefinedTerm
    221 Nfde2584d90e24ca7aaf7bff336f22b34 rdf:first sg:person.015054254665.16
    222 rdf:rest N9f7f9dd66ccb4b8cb7829f72a6807647
    223 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    224 schema:name Medical and Health Sciences
    225 rdf:type schema:DefinedTerm
    226 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    227 schema:name Clinical Sciences
    228 rdf:type schema:DefinedTerm
    229 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    230 schema:name Oncology and Carcinogenesis
    231 rdf:type schema:DefinedTerm
    232 sg:journal.1097543 schema:issn 0950-9232
    233 1476-5594
    234 schema:name Oncogene
    235 schema:publisher Springer Nature
    236 rdf:type schema:Periodical
    237 sg:person.011042136772.64 schema:affiliation grid-institutes:grid.272458.e
    238 schema:familyName Sakai
    239 schema:givenName Toshiyuki
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011042136772.64
    241 rdf:type schema:Person
    242 sg:person.01217377677.48 schema:affiliation grid-institutes:grid.258797.6
    243 schema:familyName Horinaka
    244 schema:givenName Mano
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217377677.48
    246 rdf:type schema:Person
    247 sg:person.01265513077.75 schema:affiliation grid-institutes:grid.272458.e
    248 schema:familyName Yoshida
    249 schema:givenName Tatsushi
    250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265513077.75
    251 rdf:type schema:Person
    252 sg:person.01356657633.67 schema:affiliation grid-institutes:grid.272458.e
    253 schema:familyName Shiraishi
    254 schema:givenName Takumi
    255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356657633.67
    256 rdf:type schema:Person
    257 sg:person.015054254665.16 schema:affiliation grid-institutes:grid.272458.e
    258 schema:familyName Nakata
    259 schema:givenName Susumu
    260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015054254665.16
    261 rdf:type schema:Person
    262 sg:person.0664220600.60 schema:affiliation grid-institutes:grid.272458.e
    263 schema:familyName Wakada
    264 schema:givenName Miki
    265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664220600.60
    266 rdf:type schema:Person
    267 sg:pub.10.1038/47412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025852070
    268 https://doi.org/10.1038/47412
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/5517 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010598958
    271 https://doi.org/10.1038/5517
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/75045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044338034
    274 https://doi.org/10.1038/75045
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/86397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004368073
    277 https://doi.org/10.1038/86397
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1038/91000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047281881
    280 https://doi.org/10.1038/91000
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1038/ng1097-141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040087526
    283 https://doi.org/10.1038/ng1097-141
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1038/sj.cdd.4401187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000537525
    286 https://doi.org/10.1038/sj.cdd.4401187
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1038/sj.onc.1202543 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031105532
    289 https://doi.org/10.1038/sj.onc.1202543
    290 rdf:type schema:CreativeWork
    291 sg:pub.10.1038/sj.onc.1203025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032194524
    292 https://doi.org/10.1038/sj.onc.1203025
    293 rdf:type schema:CreativeWork
    294 sg:pub.10.1038/sj.onc.1203489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045600742
    295 https://doi.org/10.1038/sj.onc.1203489
    296 rdf:type schema:CreativeWork
    297 sg:pub.10.1038/sj.onc.1203963 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006747665
    298 https://doi.org/10.1038/sj.onc.1203963
    299 rdf:type schema:CreativeWork
    300 sg:pub.10.1038/sj.onc.1205345 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015264205
    301 https://doi.org/10.1038/sj.onc.1205345
    302 rdf:type schema:CreativeWork
    303 sg:pub.10.1038/sj.onc.1205897 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028847663
    304 https://doi.org/10.1038/sj.onc.1205897
    305 rdf:type schema:CreativeWork
    306 sg:pub.10.1038/sj.onc.1206139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023435255
    307 https://doi.org/10.1038/sj.onc.1206139
    308 rdf:type schema:CreativeWork
    309 sg:pub.10.1038/sj.onc.1206290 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047996205
    310 https://doi.org/10.1038/sj.onc.1206290
    311 rdf:type schema:CreativeWork
    312 sg:pub.10.1038/sj.onc.1207091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020888713
    313 https://doi.org/10.1038/sj.onc.1207091
    314 rdf:type schema:CreativeWork
    315 grid-institutes:grid.258797.6 schema:alternateName Department of Applied Biochemistry, Kyoto Prefectural University, 606-8522, Kyoto, Japan
    316 schema:name Department of Applied Biochemistry, Kyoto Prefectural University, 606-8522, Kyoto, Japan
    317 Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan
    318 rdf:type schema:Organization
    319 grid-institutes:grid.272458.e schema:alternateName Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan
    320 Department of Urology, Kyoto Prefectural University of Medicine, 602-8566, Kyoto, Japan
    321 schema:name Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan
    322 Department of Urology, Kyoto Prefectural University of Medicine, 602-8566, Kyoto, Japan
    323 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...